NRX PHARMACEUTICALS INCNRXP
ASignal's systematic analysis rates NRXP as Bearish.
Reflects the latest available analysis · analyzed Oct 18, 2026
The case on NRXP
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- RSI near oversold level (34.3) suggesting potential reversal
- Positive gross margin (46.64%) indicating pricing power in product offerings
- High cash position ($26.69M) relative to market cap and debt
- MACD below signal line with negative histogram, indicating bearish momentum
- Price trading below both SMA20 and SMA50, confirming downtrend
- Negative operating margin (-590.46%) and poor return on assets (-63.99%)
- Negative free cash flow ($-9.64M) and operating cash flow ($-19.77M)
- Extremely low current and quick ratios (0.86x, 0.79x) signaling liquidity risk
- Negative enterprise value to EBITDA (-4.38x) and negative P/B ratio (-650x) indicating severe financial distress
See the full verdict on NRXP
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes NRXP
Most investors never get a second opinion, let alone several. ASignal runs NRXP past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.